Literature DB >> 8882196

Mass DEC chemotherapy for control of bancroftian filariasis: comparative efficacy of four strategies two years after start of treatment.

D W Meyrowitsch1, P E Simonsen, W H Makunde.   

Abstract

The efficacy of 4 strategies for control of bancroftian filariasis using mass diethylcarbamazine (DEC) chemotherapy was evaluated and compared in 4 endemic communities in Tanzania 2 years after the start of treatment. The strategies used were the standard 12 d treatment (strategy I), a semi-annual single dose treatment (strategy II), a monthly low dose treatment (strategy III), and DEC medicated salt (strategy IV). Treatment took place during the first study year, and no treatment was given during the second year. Among individuals who were microfilaraemic before treatment, the microfilaria (mf) clearance rates were 41.5%, 75.0%, 84.0% and 89.1%, and the pre-treatment mf geometric mean intensities (GMIs) were reduced by 97.1%, 98.9%, 99.8% and 99.8%, for strategies I, II, III and IV, respectively, 2 years after starting treatment. Statistical analysis indicated that strategies III and IV were equally effective, and superior in clearing microfilaraemias and in reducing mf GMIs compared to strategies I and II; strategy II was significantly more effective than strategy I. The rate of occurrence of new cases of microfilaraemia among individuals who were amicrofilaraemic during the pre-treatment surveys was negligible over the study period in all communities. In all the communities combined, 66.6% of males presenting hydrocele before treatment, and 61.5% of individuals presenting elephantiasis before treatment, showed improvements in these conditions 2 years after the start of treatment, either as a reduction in size or complete disappearance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882196     DOI: 10.1016/s0035-9203(96)90534-9

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

1.  Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis.

Authors:  Patrick Lammie; Trevor Milner; Robin Houston
Journal:  Bull World Health Organ       Date:  2007-07       Impact factor: 9.408

2.  Current evidence on the use of antifilarial agents in the management of bancroftian filariasis.

Authors:  Sumadhya Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  J Trop Med       Date:  2010-12-30

3.  Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis.

Authors:  Alexander Yaw Debrah; Sabine Mand; Sabine Specht; Yeboah Marfo-Debrekyei; Linda Batsa; Kenneth Pfarr; John Larbi; Bernard Lawson; Mark Taylor; Ohene Adjei; Achim Hoerauf
Journal:  PLoS Pathog       Date:  2006-09       Impact factor: 6.823

4.  Assessing endgame strategies for the elimination of lymphatic filariasis: A model-based evaluation of the impact of DEC-medicated salt.

Authors:  Morgan E Smith; Brajendra K Singh; Edwin Michael
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

5.  Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis.

Authors:  Swarnali Sharma; Morgan E Smith; James Reimer; David B O'Brien; Jean M Brissau; Marie C Donahue; Clarence E Carter; Edwin Michael
Journal:  PLoS Negl Trop Dis       Date:  2019-07-01

6.  Global eradication of lymphatic filariasis: the value of chronic disease control in parasite elimination programmes.

Authors:  Edwin Michael; Mwele N Malecela; Mihail Zervos; James W Kazura
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

7.  Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.

Authors:  Dziedzom K de Souza; Collins S Ahorlu; Susan Adu-Amankwah; Joseph Otchere; Sedzro K Mensah; Irene A Larbi; George E Mensah; Nana-Kwadwo Biritwum; Daniel A Boakye
Journal:  Trials       Date:  2017-10-02       Impact factor: 2.279

Review 8.  Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.

Authors:  Philip J Budge; Carly Herbert; Britt J Andersen; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2018-05-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.